The Digital Biomarkers Market is gaining momentum as healthcare systems move toward continuous, data-driven patient monitoring. Digital biomarkers provide measurable information from digital devices and applications that can help assess disease progression, treatment response, and patient behavior. Their application across chronic disease management, mental health monitoring, personalized medicine, and clinical trials is increasing.

Wearable devices, mobile health applications, remote patient monitoring, and telehealth solutions are key technology areas supporting market development. Advances in artificial intelligence, sensor technology, and data analytics are improving the ability to process large volumes of real-world health information. Pharmaceutical companies are also increasingly interested in digital endpoints for clinical development.

North America continues to hold a significant position in the market, supported by regulatory developments and established digital healthcare infrastructure. Asia-Pacific is expected to be one of the fastest-growing regions, driven by expanding digital health programs, smartphone adoption, and healthcare modernization. Europe remains an important market due to its focus on health-data interoperability and digital healthcare solutions.

Future growth is expected to be supported by increasing use of digital biomarkers in drug development and decentralized clinical trials. The global market is forecast to increase from USD 4.18 billion in 2025 to USD 23.02 billion by 2035.